Argentina

Laboratorio Elea has struck a deal with Nichi-Iko Pharmaceutical to market the Japanese firm’s infliximab biosimilar in Argentina.

Number of regulators formally agreeing to work toward creating Latin American regulator is growing.

The number of regulators formally agreeing to work towards creating a Latin American regulator is growing.

Medicines regulators from Mexico, Colombia and Cuba have pledged to create a new agency for medicines and medical devices of Latin America and the Caribbean.

The Russian Direct Investment Fund says it has 20 technology transfer and production agreements in place in 13 countries across the world.

While the US and EU regulators seem less than keen on the data package offered to date on COVID-19 Vaccine AstraZeneca, Latin American countries are moving quickly to follow the UK in backing the cost-effective and more-easily deliverable option.

The latest round-up from the Pink Sheet of developments relating to COVID-19.

Argentina’s off-patent industry association, CILFA, has joined global body the IGBA as an associate member.

Henlius has struck a deal with Mabxience to market its HLX02 trastuzumab biosimilar in Argentina, Uruguay and Paraguay.

Latin American countries are continuing to pursue a strategy of jointly negotiating medicine prices to get a better deal on expensive medicines. However, manufacturers have expressed doubt that this is the best way forward.

A buyers club in the UK is planning to import generic versions of Vertex’s cystic fibrosis drugs that are not available on the NHS.  Some commentators think such clubs may become more common.

A buyers club in the UK is planning to import generic versions of Vertex’s cystic fibrosis drugs that are not available on the NHS.  Some commentators think such clubs may become more common.

Sanofi Consumer Healthcare is utilizing emerging digital technology to take a bigger slice of the Latin American OTC market. Through a partnership deal, e-commerce and delivery firm Rappi will promote and sell Sanofi's brands to consumers across seven Latin American markets. 

Countries in South America have negotiated lower prices for the immunosuppressant tacrolimus and have their sights on high-cost oncology treatments. However, they have slammed companies selling new hepatitis C treatments for their inflexibility.

Medicines regulators in Mexico and Argentina have agreed to exchange good manufacturing practices inspection certificates.

Argentina could be on the way to creating a national health technology appraisal organization.

The EU is once again facing criticism for its pursuit of investor-state dispute settlement-like mechanisms.

The European Commission expects talks will resume in a matter of weeks for an EU-Mercosur trade deal, which would increase intellectual property rights protection for originator medicines in the Latin American markets.

The European Commission expects talks will resume in a matter of weeks for an EU-Mercosur trade deal, which would increase intellectual property rights protection for originator medicines in the Latin American markets.

Argentina’s patent office, INPI, has rejected an application for a key patent relating to Gilead’s hepatitis C drug Sovaldi (sofosbuvir).